Wangzhi Li

Wangzhi Li has a diverse and extensive work experience. Wangzhi started their career as an intern at the New York City Investment Fund in 2010, followed by an internship at the Technology Transfer Office of Cold Spring Harbor Laboratory in 2012. In the same year, they also founded the Chinese Life Science Professionals Association (CLSPA), where they served as the Founding President. Under their leadership, the CLSPA grew into a well-recognized organization, organizing influential events and establishing alliances with other premium organizations.

In 2013, Wangzhi worked as a Summer Associate at Easton Capital Investment Group, where they developed a novel investment strategy and sourced healthcare investment opportunities. Wangzhi joined the Ladenburg Thalmann in 2014 and held various roles, including Vice President and Managing Director. During their time at Ladenburg Thalmann, they focused on biotech equity research and played a crucial role in the development of the company.

Prior to working at Ladenburg Thalmann, Wangzhi conducted biomedical research at Cold Spring Harbor Laboratory. Wangzhi made significant contributions in the field of epigenetics and authored articles in prestigious journals, including Nature Cell Biology and Cell Stem Cell. Wangzhi also served as a guest editor and reviewer for various scientific journals.

Overall, Wangzhi Li has demonstrated strong leadership skills, expertise in investment and research, and a track record of success in the life sciences industry.

Wangzhi Li holds a Ph.D in Biomedicine from Cold Spring Harbor Laboratory & Stony Brook University, which was completed from 2006 to 2013. Additionally, Wangzhi Li obtained a Certificate in Fundamentals of Bioscience Industry from the State Center for Biotechnology, New York in 2011. Prior to that, Wangzhi Li received a Bachelor's degree in Biological Sciences from Xiamen University, earned from 2002 to 2006. Furthermore, there is information about additional certifications obtained by Wangzhi Li from the Financial Industry Regulatory Authority (FINRA), including Series 63, Series 7, Series 86, and Series 87. However, specific details regarding the dates of obtaining these certifications are not provided.